Results 91 to 100 of about 331,825 (303)
Micropapillary Bladder Cancer: Insights from the National Cancer Database
Bladder Cancer, 2016 Introduction: Micropapillary bladder cancer (MPBC) is a variant histology of urothelial carcinoma (UC) that is associated with poor outcomes however given its rarity, little is known outside of institutional reports.
Wilson Sui +7 more
doaj +1 more source
, 2017 Given the promising control of bladder cancer achieved by combined chemotherapy/radiotherapy with selective transurethral resection, obstacles remain to the treatment of unresectable bladder cancer.
Tsai, Yu-Chieh;Yeh, Chih-Hsien;Tzen, Kai-Yuan;Ho, Pei-Yin;Tuan, Tsung-Fan;Pu, Yeong-Shiau;Cheng, Ann-Lii;Cheng, Jason Chia-Hsien +1 more
core +1 more source
Epidemiology of Bladder Cancer
, 2020 Based on the latest GLOBOCAN data, bladder cancer accounts for 3% of global cancer diagnoses and is especially prevalent in the developed world. In the United States, bladder cancer is the sixth most incident neoplasm.
Saginala, Barsouk, Padala, Aluru, Rawla
core +1 more source
Concurrent Bladder Lymphoma and Bladder Cancer Presenting as Metastatic Bladder Cancer
The World Journal of Men's Health, 2012 Malignant lymphoma of the bladder is a rare lesion, representing approximately 0.2% of the primary lesions and approximately 1.8% of the secondary lesions. A disseminated lymphoma presenting as a bladder mass is an infrequent phenomenon. The authors report the case of a 71-year-old patient with concurrent bladder lymphoma and bladder cancer presenting ...
Kim, Jae Heon +5 more
openaire +2 more sources
O‐GlcNAcylated TAP1 Impairs Antigen Presentation and Promotes Immune Evasion in Bladder Cancer
Advanced Science, EarlyView.This article unveils a critical mechanism of immune evasion in bladder cancer, which the O‐GlcNAc modification of TAP1 disrupts antigen presentation. This modification triggers HLA‐A degradation, shielding tumor cells from CD8+ T cell attack. The findings highlight targeting this pathway as a promising therapeutic avenue to sensitize tumors to ...
Jinpeng Wu +10 more
wiley +1 more source
Chemotherapy for Invasive Bladder Cancer: Five Simple Rules Learned Over 30 Years
Bladder Cancer, 2015 Invasive, clinically non-metastatic bladder cancer has a cure rate of only 50% , when all T stages are considered. The pattern of relapse is dominated by systemic spread, provided that optimal surgery is practiced.
Derek Raghavan
doaj +1 more source
Advanced Science, EarlyView.A single‐cell atlas of pancreatic ductal adenocarcinoma development reveals progressive ductal‐fibroblast‐immune crosstalk. Tumor‐derived LAMB3 drives the formation of immunosuppressive LRRC15+ fibroblasts through the ITGB1/FAK/MAPK/FOSL2 signaling. Glycolytic reprogramming upregulates LAMB3 and correlates with LRRC15+ fibroblast enrichment.
Xuqing Shi +23 more
wiley +1 more source
, 2014 This article reviews human observations on pioglitazone and bladder cancer risk. The PROspective pioglitAzone Clinical Trial In macroVascular Events trial showed an imbalance in bladder cancer between users of pioglitazone and placebo (14 versus six ...
Tseng, Chin-Hsiao, 曾慶孝
core +1 more source
Advanced Science, EarlyView.THUMPD1 drives a tumor‐suppressive signaling cascade in lung adenocarcinoma by promoting IGF2R expression. IGF2R associates with PPP2R1A to suppress AKT and activate AMPK, leading to SLC31A1 upregulation and copper accumulation. Elevated copper disrupts mitochondrial metabolism and induces excessive mitophagy, thereby restraining tumor growth and ...
Kai Wu +10 more
wiley +1 more source
Bladder Cancer, 2018 Background: Adjuvant intravesical instillations with bacillus Calmette-Guérin (BCG) is the recommended treatment option for patients with intermediate-and high-risk non-muscle invasive bladder cancer (NMIBC).
Joep J. de Jong +4 more
doaj +1 more source